title: [Gastrointestinal stromal tumors].
abstract: Gastrointestinal stromal tumors (GIST) are the most common sarcomas of the gastrointestinal tract. They affect all segments of the digestive tract. They develop from the interstitial cells of Cajal. Mutations in the Kit gene is present in 86% of cases and in PDGFR gene in 15% of cases. The marker CD 117 is present in 95% of cases. Surgery is the standard treatment in localized forms. The tyrosine kinase inhibitor, imatinib is standard in first-line metastatic gastrointestinal stromal tumors, as well as adjuvant treatment after surgery. Sunitinib is the standard in second line.
authors.affiliation: Institut national d'oncologie, service d'oncologie médicale, 10100 Rabat, Maroc. sakina.sekkate@yahoo.fr
authors.forename: Sakina
authors.initials: S
authors.lastname: Sekkate
authors.forename: Mouna
authors.initials: M
authors.lastname: Kairouani
authors.forename: Halima
authors.initials: H
authors.lastname: Abahssain
authors.forename: Badr
authors.initials: B
authors.lastname: Serji
authors.forename: Saber
authors.initials: S
authors.lastname: Boutayeb
authors.forename: Hind
authors.initials: H
authors.lastname: Mrabti
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003937:Diagnosis, Differential; D013505:Digestive System Surgical Procedures; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D011379:Prognosis